Skip to content
Hair Pipeline
← Remedies and supplements

Does weight loss cause hair loss?

Yes, it can. Rapid weight loss is a recognised trigger of telogen effluvium, in which many more hairs than usual enter the resting phase and fall out a few months later, and dermatologists say it usually gets better without treatment. Meta-analyses put hair loss after bariatric surgery at about half of patients, less often with longer follow-up. In the US labels of Wegovy and Zepbound, hair loss was reported by about 3% to 6% of patients on the drug against about 1% on placebo, more often by women, and both labels say it was associated with weight reduction; whether the drugs cause it beyond the weight loss itself has not been established.

Why losing weight fast can thin hair

Telogen effluvium is shedding that follows a shock to the body. Normally about 15% of scalp hairs are resting before they fall; in telogen effluvium the share rises to 30% or more, according to the British Association of Dermatologists, which lists "marked weight loss and extreme dieting" among its common triggers, with childbirth, illness and surgery. A 1976 report described nine people who lost 11.7 to 24.75 kg on vigorous weight-loss programmes and had "profuse hair loss" two to five months after starting, with 25% to 50% of their hairs resting; three had lost hair after earlier successful diets too. The authors thought rigorous calorie restriction was the cause, leaving too little energy for the hair matrix, the part of the follicle that makes hair. In a 2024 Korean study of 140 people with telogen effluvium after weight loss, they had lost 15% of their weight on average, at 3.5 kg a month, and the women had lost weight more slowly than the men. The study had no comparison group of people who lost weight without shedding.

After weight-loss surgery

Hair loss is one of the most common complaints after bariatric surgery. A 2021 meta-analysis of 18 studies and 2,538 patients put it at 57%, but individual studies ranged from under 1% to 80%, the observational studies were of low or moderate quality, and the authors note that patients' reports of hair loss are very subjective. It fell from 58% in studies that followed patients for less than a year to 35% in those that followed them for a year or more. A 2025 update pooled 41 studies and 7,044 patients and found 47%, with hair loss more common after gastric bypass than after sleeve gastrectomy, and more common still after a duodenal switch. In a 2021 study of 156 women after a sleeve, 72% reported hair loss, which most often began in the third or fourth month and lasted 5.5 months on average; none was left with permanent hair loss.

What the US labels say

The US prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide) lists hair loss among their side effects and says it was "associated with weight reduction". In three adult trials of Wegovy injections it was reported by 3.3% of patients on the drug and 1% on placebo (4% and 2% of women, 0.9% and none of men); trials of a higher dose found 5.8% against 1.0%, and a trial in adolescents 4% against none. In two Zepbound trials it was 4% to 5%, depending on the dose, against 1% on placebo, and 7.1% of women and 0.5% of men on the drug; no one stopped Zepbound because of it. The US labels warn that rates from one drug's trials cannot be directly compared with another's.

What the European product information says

Wegovy's European product information, pooling four trials, gives 2.5% against 1.0%, and 5.3% against 1.0% at a higher dose, mainly mild, with most patients recovering while staying on treatment; for Wegovy tablets, 6.4% against 2.0%, all mild or moderate, half resolved by the end of the trial. In both, hair loss was reported more often in patients who lost 20% of their weight or more. Mounjaro, tirzepatide's brand name in Europe, lists it as common, between 1 in 100 and 1 in 10 patients, mainly in people treated for overweight or obesity. In France both drugs are prescription-only, and the medicines agency ANSM says they must not be used to lose weight for cosmetic reasons, by people who are neither overweight nor obese and have no weight-related health problems.

The drug or the weight loss?

Whether these drugs affect hair beyond the weight loss is not settled. A 2026 systematic review of 24 studies, most of them drug-safety databases and health-record cohorts, found semaglutide and tirzepatide most often linked to hair loss, named rapid weight loss as a potential contributor, particularly to telogen effluvium, and called for large randomised trials to establish causality. A 2026 study in the BMJ, of adults with type 2 diabetes treated at Penn Medicine in the US, found non-scarring hair loss diagnosed more often in about 12,000 people who started a GLP-1 drug than in people who started either of two other kinds of diabetes drug; the link weakened after a statistical check for bias, and the authors note that the absolute risk is low. The US label of Ozempic, semaglutide's diabetes brand, lists hair loss only among voluntary post-marketing reports, for which a link to the drug cannot always be established. In January 2025 the EU's drug-safety committee, the PRAC, decided against adding hair loss to the European information for Ozempic and Rybelsus, judging the data insufficient to conclude a causal link, according to a report published by France's medicines agency.

When it starts and whether it grows back

Shedding usually shows a few months after the trigger, around three months according to the British Association of Dermatologists, two to four months according to DermNet, a dermatology reference site, and two to three months according to the French Society of Dermatology's patient site. The BAD says the shedding phase lasts three to six months, after which new hair grows, though it may take many months to regain its former volume; telogen effluvium usually gets completely better without treatment, and medication does not speed regrowth. DermNet says hair fall tapers back to normal over six to nine months in most cases, but recovery may be incomplete in some, and the French site says hair usually grows back within a few months. In the 2024 Korean study, shedding improved without treatment after 4.8 months on average. Shedding that lasts more than six months is called chronic, and the BAD says it can come back if an underlying cause such as iron deficiency is not treated.

Iron, zinc and protein

Low nutrient levels may play a part, but the studies of blood levels show links, not cause. In the 2021 surgery meta-analysis, patients with hair loss had lower ferritin and folic acid, in two studies each, and lower zinc at the edge of statistical significance, in four studies of which two found no difference. Blood iron and vitamin B12 did not differ, and the authors found the evidence insufficient to blame iron deficiency. At a hospital near Paris, among 555 patients in their first year after surgery and 494 three years or more after, those with hair loss had lower blood protein and iron markers, and no difference in zinc or B vitamins. The ANSM is monitoring a potential signal of nutritional deficiencies linked to rapid weight loss on GLP-1 drugs, and its pharmacovigilance report notes that deficiencies are risk factors for hair loss.

Trials of supplements to prevent it

We found one small trialof supplements to prevent it, run in Iran and published in 2021 in a journal not indexed in PubMed. Of 85 women analysed after a sleeve, those randomly given a routine multivitamin, alone or with zinc, iron and B vitamins, had fewer hairs on one square centimetre at the front of the scalp three months after surgery than before; those also given wheat and sesame protein and two amino acids had more. The paper reports no funding and cites no trial registration. Two company-sponsored trials registered in 2026, in women starting these drugs or already shedding on them, have no results yet.

Related questions

Sources

  1. Telogen effluvium (a type of hairloss) · British Association of Dermatologists, 2025
  2. Alopecia in crash dieters · JAMA, 1976 · PMID 946869
  3. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study · Annals of Dermatology, 2024 · PMID 39623615
  4. Hair Loss After Metabolic and Bariatric Surgery: a Systematic Review and Meta-analysis · Obesity Surgery, 2021 · PMID 33675022
  5. Hair Loss and Metabolic and Bariatric Surgery: An Updated Systematic Review and Meta-analysis · Obesity Surgery, 2025 · PMID 40388098
  6. Hair Loss After Sleeve Gastrectomy and Effect of Biotin Supplements · Journal of Laparoendoscopic & Advanced Surgical Techniques, 2021 · PMID 32762597
  7. WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use. Full prescribing information · US Food and Drug Administration (label via DailyMed, National Library of Medicine), 2026
  8. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Full prescribing information · US Food and Drug Administration (label via DailyMed, National Library of Medicine), 2026
  9. Wegovy : EPAR - Product Information · European Medicines Agency, 2026
  10. Mounjaro : EPAR - Product Information · European Medicines Agency, 2026
  11. Analogues du GLP-1 indiqués dans le traitement de l’obésité : l’ANSM fait évoluer leurs conditions de prescription et de délivrance · ANSM, 2025
  12. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling · Science Progress, 2026 · PMID 41998799
  13. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation · BMJ, 2026 · PMID 42486607
  14. OZEMPIC (semaglutide) injection, for subcutaneous use. Full prescribing information · US Food and Drug Administration (label via DailyMed, National Library of Medicine), 2026
  15. Rapport d'enquête de pharmacovigilance. Enquête nationale sur les effets indésirables associés aux agonistes du récepteur du glucagon-like peptide 1 (GLP-1) (rapport n°2) · ANSM (CRPV de Montpellier et de Limoges), 2026
  16. Telogen effluvium (hair shedding) · DermNet, 2019
  17. Tout savoir sur l'alopécie · Dermato-Info (Société Française de Dermatologie), 2026
  18. What Are the Micronutrient Deficiencies Responsible for the Most Common Nutritional Symptoms After Bariatric Surgery? · Obesity Surgery, 2020 · PMID 31960214
  19. The Effects of Essential Amino Acids, Zinc, and Iron Supplementation on the Prevention of Early Hair Loss After Sleeve Gastrectomy · Annals of Bariatric Surgery, 2021
  20. Surveillance des aGLP-1 : l’ANSM confirme le rapport bénéfice/risque favorable lorsque ces médicaments sont utilisés conformément aux recommandations · ANSM, 2026
  21. Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists (NCT07484061) · ClinicalTrials.gov, 2026
  22. Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use (NCT07783113) · ClinicalTrials.gov, 2026

Checked against its sources on 2026-11-01, by us, not by a doctor. A research register, not medical advice: talk to a dermatologist about your own case. See why we're not doctors.